ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tigulixostat

Also written as “Tigulixostat”, “LC350189 formulated capsule” and “IBI128”.

Its studies are mostly in Gout · Hyperuricemia, led by 2 companies.

Drug pageTigulixostat: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 16, 202210 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LG Chemits history only80 open or runningphase 3since Oct 16, 2022May 19, 2011none ahead
Innovent Biologics21 open or runningphase 3since Feb 3, 2026Jul 2, 2024Apr 30, 2027phase 3 · NCT07414394

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Innovent Biologics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named tigulixostatINNProposed as its International Nonproprietary Name in WHO's List 124 · before, IBI128
  2. Jul 2, 2024First study: phase 2 study in GoutFirst studyNCT06501534 · 84 enrolled · China
  3. Feb 3, 2026Phase 3 study in GoutPhase 3 reachedNCT07414394 · 600 enrolled · China

Ahead

  1. Apr 30, 2027Primary completion: phase 3 study in GoutNCT07414394

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Innovent Biologics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07414394Gout · China3Active, not recruitingApr 30, 2027600
NCT06501534Gout · China2CompletedDec 13, 202484

How it is read

Names in the registry

  • “Tigulixostat”, 4 entries
  • “LC350189 formulated capsule”, 1 entry
  • “IBI128”, 1 entry
  • “LC350189 200mg”, 1 entry
  • “LC350189 600mg”, 1 entry

Codes read as this program: IBI128.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.